SCHEMBL6713166

SCHEMBL6713166

CC(C)c1cnc(N(C(N)=O)c2ccc(-c3nc4ccccc4[nH]3)cc2)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
PKM P14618 4/20 0.43
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
KMT2A Q03164 1/20 0.43
CHEK2 O96017 3/20 0.42
HPSE Q9Y251 2/20 0.42
FASN P49327 2/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
GFER P55789 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6508734 0.81 KDM4E (0.59) NPC1RAB9AKDM4EALDH1A1PKM
SCHEMBL6711707 0.79 MLYCD (0.47) NPC1RAB9AALDH1A1SMN1; SMN2LMNA
SCHEMBL27570619 0.76 CDK2 (0.38) ALDH1A1SMN1; SMN2
SCHEMBL7257113 0.76 CDK2 (0.38) ALDH1A1SMN1; SMN2LMNAGAA
SCHEMBL27572548 0.76 CDK2 (0.38) ALDH1A1SMN1; SMN2LMNAGAA
SCHEMBL27574287 0.75 CCNE1 (0.37) ALDH1A1SMN1; SMN2KMT2A
SCHEMBL6710898 0.75 MLYCD (0.38) ALDH1A1SMN1; SMN2
SCHEMBL27574281 0.74 CDK2 (0.38) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL27551074 0.74 CDK2 (0.38) ALDH1A1SMN1; SMN2LMNACHEK2GAA
SCHEMBL6287985 0.73 HPSE (0.66) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 NPC1 2685/4885RAB9A 2674/4885KDM4E 2087/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 NPC1 2685/4885RAB9A 2674/4885KDM4E 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.